In coordination with this, a first clinical trial using tadekinig alfa, a human recombinant IL-18 binding protein (BP), in patients with RA and PsO failed to demonstrate therapeutic efficacy [56] despite the elevated circulating levels and tissue expression of IL-18 has been described in these diseases [12, 57–64]. The gene discussed is IL18; the disease is rheumatoid arthritis.